Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and at-risk individuals.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Investor sentiment on Moderna turned bearish over the weekend despite FDA approval of its new COVID-19 vaccine, mNEXSPIKE, which showed higher efficacy and a favorable safety profile.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation introduces uncertainty into the nation's defense strategy against H5N1 avian influenza despite positive clinical trial results.
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally.
CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. The Company plans to resubmit the BLA later this year, after vaccine efficacy data from the ongoing Phase 3 trial of its investigational seasonal influenza vaccine, mRNA-1010, are available. Moderna continues to expect interim data from the mRNA-1010 trial to be available this summer.
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
